000136016 001__ 136016
000136016 005__ 20240229105049.0
000136016 0247_ $$2doi$$a10.1007/s00262-018-2171-7
000136016 0247_ $$2pmid$$apmid:29799076
000136016 0247_ $$2ISSN$$a0340-7004
000136016 0247_ $$2ISSN$$a1432-0851
000136016 0247_ $$2altmetric$$aaltmetric:43010497
000136016 037__ $$aDKFZ-2018-00716
000136016 041__ $$aeng
000136016 082__ $$a610
000136016 1001_ $$0P:(DE-He78)72fa0d570de4683b3eae28f335924d81$$aBauer, Corinne$$b0$$eFirst author$$udkfz
000136016 245__ $$aT-lymphocyte profiles differ between keratoacanthomas and invasive squamous cell carcinomas of the human skin.
000136016 260__ $$aBerlin$$bSpringer$$c2018
000136016 3367_ $$2DRIVER$$aarticle
000136016 3367_ $$2DataCite$$aOutput Types/Journal article
000136016 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1659518871_29254
000136016 3367_ $$2BibTeX$$aARTICLE
000136016 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000136016 3367_ $$00$$2EndNote$$aJournal Article
000136016 500__ $$aDKFZ-ZMBH-Allianz
000136016 520__ $$aT-lymphocytes are involved in tumor progression and regression. Actinic keratoses (AK) are atypical proliferations of keratinocytes of the skin. Some AK progress into invasive cutaneous squamous cell carcinomas (cSCC). Keratoacanthomas (KA) are either classified as a cSCC subtype or a benign tumor with histologic resemblance to well-differentiated cSCC as it is supposed to regress spontaneously. In contrast, cSCC represent malignant tumors that may metastasize.To compare the T-lymphocyte profiles of AK, KA and cSCC in relation to PD-L1 expression.Tissue micro-arrays of 103 cases of AK, 43 cases of KA and 106 cases of cSCC were stained by immunohistochemistry for E-cadherin, CD3, CD4, CD8, FOXp3, and the receptor-ligand pair PD-1/PD-L1. Immunohistological scores were computationally determined to assess PD-L1 expression as well as the expression profiles of T-lymphocytes.AK had lower numbers of CD3+ and PD-1+ cells compared to KA and lower numbers of CD3+, CD8+ and PD-1+ cells in comparison with cSCC. KA showed significantly higher numbers of CD4+ and FOXp3+ cells as well as lower numbers of CD8+ cells in comparison with invasive cSCC. cSCC expressed significantly more PD-L1 in comparison with AK and KA. Among cSCC PD-L1 expression was higher in moderately and poorly-differentiated cSCC than in well-differentiated cSCC. Increased PD-L1 expression also correlated with increased numbers of CD4+, CD8+ and FOXp3+ cells in cSCC.Tumor-associated T-lymphocyte infiltrates showed significant differences between AK, KA and invasive cSCC. PD-L1 expression correlated with invasion of T-cell infiltrates in invasive cSCC.
000136016 536__ $$0G:(DE-HGF)POF3-311$$a311 - Signalling pathways, cell and tumor biology (POF3-311)$$cPOF3-311$$fPOF III$$x0
000136016 588__ $$aDataset connected to CrossRef, PubMed,
000136016 7001_ $$0P:(DE-He78)81cd72bf4d0bacc59dc1d2b3b5c27be7$$aAbdul Pari, Ashik Ahmed$$b1$$udkfz
000136016 7001_ $$0P:(DE-He78)38be34240daf8b47325afc7910e77f7b$$aUmansky, Viktor$$b2$$udkfz
000136016 7001_ $$0P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3$$aUtikal, Jochen$$b3$$udkfz
000136016 7001_ $$0P:(DE-He78)c1895aa471c7ac9c7173045464b69b31$$aBoukamp, Petra$$b4$$udkfz
000136016 7001_ $$0P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b$$aAugustin, Hellmut$$b5$$udkfz
000136016 7001_ $$aGoerdt, Sergij$$b6
000136016 7001_ $$aGéraud, Cyrill$$b7
000136016 7001_ $$0P:(DE-He78)28b708d8e88fbb959e31ff6770aaa6c7$$aFelcht, Moritz$$b8$$eLast author$$udkfz
000136016 773__ $$0PERI:(DE-600)1458489-x$$a10.1007/s00262-018-2171-7$$gVol. 67, no. 7, p. 1147 - 1157$$n7$$p1147 - 1157$$tCancer immunology immunotherapy$$v67$$x1432-0851$$y2018
000136016 909CO $$ooai:inrepo02.dkfz.de:136016$$pVDB
000136016 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)72fa0d570de4683b3eae28f335924d81$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000136016 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)81cd72bf4d0bacc59dc1d2b3b5c27be7$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000136016 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)38be34240daf8b47325afc7910e77f7b$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000136016 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000136016 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c1895aa471c7ac9c7173045464b69b31$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000136016 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000136016 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)28b708d8e88fbb959e31ff6770aaa6c7$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000136016 9131_ $$0G:(DE-HGF)POF3-311$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vSignalling pathways, cell and tumor biology$$x0
000136016 9141_ $$y2018
000136016 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000136016 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000136016 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000136016 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000136016 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER IMMUNOL IMMUN : 2015
000136016 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000136016 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000136016 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000136016 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000136016 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000136016 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000136016 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000136016 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000136016 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000136016 9201_ $$0I:(DE-He78)A190-20160331$$kA190$$lA190 Vaskuläre Onkologie und Metastasierung$$x0
000136016 9201_ $$0I:(DE-He78)G300-20160331$$kG300$$lKKE Dermatoonkologie$$x1
000136016 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000136016 980__ $$ajournal
000136016 980__ $$aVDB
000136016 980__ $$aI:(DE-He78)A190-20160331
000136016 980__ $$aI:(DE-He78)G300-20160331
000136016 980__ $$aI:(DE-He78)L101-20160331
000136016 980__ $$aUNRESTRICTED